Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 12, Issue 530, Pages eaax0876
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-02-13
DOI
10.1126/scitranslmed.aax0876
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy
- (2019) Lian He et al. Journal of Biological Engineering
- Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
- (2018) Xuexiang Du et al. CELL RESEARCH
- Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
- (2018) Young Kwang Chae et al. Journal for ImmunoTherapy of Cancer
- Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
- (2018) Florence T. H. Wu et al. BRITISH JOURNAL OF CANCER
- Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer
- (2018) Emmett V. Schmidt Seminars in Immunopathology
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Two-step enhanced cancer immunotherapy with engineeredSalmonella typhimuriumsecreting heterologous flagellin
- (2017) Jin Hai Zheng et al. Science Translational Medicine
- Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models
- (2017) In Young Hwang et al. Nature Communications
- New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
- (2017) Isabel Corraliza-Gorjón et al. Frontiers in Immunology
- Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy
- (2017) Yaozhong Hu et al. Frontiers in Immunology
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- Oral Administration of the Probiotic Strain Escherichia coli Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction
- (2017) Thomas Secher et al. Frontiers in Immunology
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Synchronized cycles of bacterial lysis for in vivo delivery
- (2016) M. Omar Din et al. NATURE
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Challenges to production of antibodies in bacteria and yeast
- (2015) Yong Jae Lee et al. JOURNAL OF BIOSCIENCE AND BIOENGINEERING
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Programmable probiotics for detection of cancer in urine
- (2015) Tal Danino et al. Science Translational Medicine
- Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
- (2015) Jonathan Rios-Doria et al. NEOPLASIA
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) Kibem Kim et al. Journal for ImmunoTherapy of Cancer
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
- (2013) W. L. Redmond et al. Cancer Immunology Research
- Escherichia coli Nissle 1917 Targets and Restrains Mouse B16 Melanoma and 4T1 Breast Tumors through Expression of Azurin Protein
- (2012) Yunlei Zhang et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vivo Gene Expression Dynamics of Tumor-Targeted Bacteria
- (2012) Tal Danino et al. ACS Synthetic Biology
- A sensing array of radically coupled genetic ‘biopixels’
- (2011) Arthur Prindle et al. NATURE
- Sequential Establishment of Stripe Patterns in an Expanding Cell Population
- (2011) C. Liu et al. SCIENCE
- A synchronized quorum of genetic clocks
- (2010) Tal Danino et al. NATURE
- A Synthetic Genetic Edge Detection Program
- (2009) Jeffrey J. Tabor et al. CELL
- Tumor Invasion of Salmonella enterica Serovar Typhimurium Is Accompanied by Strong Hemorrhage Promoted by TNF-α
- (2009) Sara Leschner et al. PLoS One
- A fast, robust and tunable synthetic gene oscillator
- (2008) Jesse Stricker et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started